In vitro Diagnostics of Neurodegenerations
The most common neurodegenerative disorders include Alzheimer’s disease and Parkinson’s disease. There are also many others like dementia with Lewy-bodies, Picks’s disease, or Creutzfeldt-Jakob disease.
They all follow a common path of disease progression, which begins up to 15 years before the patients or their relatives start to notice first symptoms. Today there are approx. three million new cases per year in the EU and the USA, which will nearly double by 2050.
The first step to therapy or treatment is an accurate, timely and reliable diagnosis.
What are We Doing About it?
Based on proprietary technology, we develop an in vitro diagnostic process that directly exploits pathological disease biomarkers for the sensitive and specific laboratory analysis of neurodegenerative disorders.
Our Key Advantages:
- One unique technology for multiple diseases.
- Optimal sensitivity. We detect neurodegenerative diseases with great reliability.
- Optimal specificity. We use biomarkers that exist only in affected people and thus keep false-positives at a minimum.
- Great potential for future pre-clinical diagnostics. Future therapies will require early and accurate diagnosis.
- One technology for multiple types of specimens including lumbal liquor (CSF), tissue biopsies or even blood.